Authors
Loading...
Randomized trial demonstrates CXCL11's role in forming immunosuppressive barriers in pancreatic cancer, indicating potential therapeutic targets.
Wei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: